Jennifer Rawls, APRN
Psychiatric/Mental Health · Little Rock, ARNPI 1831770981
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 205 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 27.7% of the total. Reporting peaked in 2022 at $1,042 and has fallen 66.5% since, to $349 in 2025.
Across 205 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$936
- Johnson & Johnson$506
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$333
- Neurocrine Biosciences, Inc.$308
- Otsuka America Pharmaceutical, Inc.$267
- Teva Pharmaceuticals USA, Inc.$243
- plus $788 from 12 others
What the payments were for
- Food & beverage$3,380100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 85 | $936 |
| Johnson & Johnson | 18 | $506 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $333 |
| Neurocrine Biosciences, Inc. | 18 | $308 |
| Otsuka America Pharmaceutical, Inc. | 13 | $267 |
| Teva Pharmaceuticals USA, Inc. | 14 | $243 |
| Alkermes, Inc. | 10 | $213 |
| Axsome Therapeutics, Inc. | 9 | $187 |
| Lundbeck LLC | 6 | $121 |
| Vanda Pharmaceuticals Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Corium, LLC | 3 | $35 |
| Neuronetics, Inc. | 1 | $32 |
| Sun Pharmaceutical Industries Inc. | 2 | $30 |
| Almatica Pharma LLC | 1 | $22 |
| Tris Pharma Inc | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$122
How this compares
$3,380 in reported general payments places this provider in the 85th percentile of 359 psychiatric/mental health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $109,977 |
| VraylarCariprazine Hcl | 21 | $29,420 |
| CaplytaLumateperone Tosylate | 11 | $17,016 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,194 |
| Lurasidone Hcl | 27 | $3,957 |
| Aripiprazole | 62 | $1,951 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 58 | $1,136 |
| Atomoxetine Hcl | 15 | $1,059 |
| Bupropion XlBupropion Hcl | 79 | $892 |
| Duloxetine Hcl | 76 | $863 |
| Quetiapine Fumarate | 93 | $676 |
| Sertraline Hcl | 160 | $560 |
| Gabapentin | 41 | $521 |
| Escitalopram Oxalate | 79 | $461 |
| Olanzapine | 20 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $308 | $109,97714 claims |
| AbbVieVraylar | $936 | $29,42021 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $333 | $17,01611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $46 | $4,19411 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $560160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 359 psychiatric/mental health providers in Arkansas.
Other psychiatric/mental health in Little Rock
- Cara MeckfesselLittle Rock$8K
- Stacey HughesLittle Rock$7K
- Michelle HeadLittle Rock$6K
- Sara JonesLittle Rock$6K
- Alicia BarosLittle Rock$6K
- Adrianne FunmakerLittle Rock$5K
- Chloe WardLittle Rock$4K
- Ashley TaylorLittle Rock$4K
- Kizzie HoustonLittle Rock$3K
- Stephanie BohannonFayetteville$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.